The latest price target for Aprea Therapeutics (NASDAQ:APRE) was reported by HC Wainwright & Co. on January 15, 2025. The analyst firm set a price target for $20.00 expecting APRE to rise to within 12 months (a possible 447.95% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Aprea Therapeutics (NASDAQ:APRE) was provided by HC Wainwright & Co., and Aprea Therapeutics reiterated their buy rating.

There is no last upgrade for Aprea Therapeutics

There is no last downgrade for Aprea Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aprea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aprea Therapeutics was filed on January 15, 2025 so you should expect the next rating to be made available sometime around January 15, 2026.

While ratings are subjective and will change, the latest Aprea Therapeutics (APRE) rating was a reiterated with a price target of $20.00 to $20.00. The current price Aprea Therapeutics (APRE) is trading at is $3.65, which is out of the analyst’s predicted range.